Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback